Latest News on PRGO

Financial News Based On Company


Advertisement
Advertisement

Perrigo Company stock hits 52-week high at $17.03 By Investing.com

https://uk.investing.com/news/stock-market-news/perrigo-company-stock-hits-52week-high-at-1703-93CH-4991503
Perrigo Company PLC (PRGO) stock reached a 52-week high of $17.03, currently trading at $17.05 with a market capitalization of $2.35 billion. The stock has seen significant growth, with a 32.06% increase over the past year and a 54.5% return in the last six months, alongside a substantial dividend yield of 7.36%. InvestingPro analysis suggests the stock is currently undervalued, and the company recently reported mixed Q3 2026 financial results, exceeding EPS expectations but falling short on revenue.

Form 4 PERRIGO Co plc: Geoffrey M. Parker (Director) For: 11 September

https://ng.investing.com/news/stock-market-news/form-4-perrigo-co-plc-geoffrey-m-parker-director-for-11-september-93CH-2808690
This article reports on a Form 4 filing for Perrigo Co plc, indicating an insider transaction involving director Geoffrey M. Parker on September 11th. The filing details are specifically related to the company's stock, PRGO, which saw a slight increase of 0.37%.

Indigestion Tablets Market To 2035: Aging Demographics and OTC Demand Drive Growth - News and Statistics

https://www.indexbox.io/blog/indigestion-tablets-market-forecast-to-2035-demand-accelerates-on-aging-populations-and-otc-self-care/
The global indigestion tablets market is projected to grow at a CAGR of 3.2% from 2026 to 2035, driven by an aging global population, increased prevalence of acid reflux and dyspepsia, and a rising consumer preference for OTC self-medication. The Asia-Pacific region is expected to be the fastest-growing market due to urbanization and increasing health awareness, while North America and Europe will maintain significant shares. Key market participants include Bayer AG, GlaxoSmithKline, Reckitt Benckiser, and Procter & Gamble, with innovation focusing on fast-acting and combination formulations.

Acetaminophen Market To 2035: Self-Care and Aging Demographics Support Forward Growth - News and Statistics

https://www.indexbox.io/blog/acetaminophen-market-forecast-to-2035-growth-driven-by-self-care-demand-and-aging-populations/
The global acetaminophen market is projected to experience steady growth through 2035, driven primarily by increasing self-care practices and an aging global population. While demand is underpinned by the universal need for pain and fever relief, the market faces challenges from high private-label penetration, regulatory constraints, and competition from substitutes like ibuprofen. E-commerce and direct-to-consumer channels are expected to continue disrupting traditional pharmacy-centric purchase journeys, with developed markets focusing on innovation and emerging economies on volume expansion.

Infant Nutrition Market Report Examines Leading Companies And Growth Opportunities

https://www.openpr.com/news/4688406/infant-nutrition-market-report-examines-leading-companies
The infant nutrition market is experiencing significant growth, projected to reach $64.3 billion by 2030, driven by rising birth rates, increased health awareness, and demand for specialized products. Key players like Abbott Laboratories and Nestlé SA are innovating with solutions like Sinergity, which mimics breast milk to improve infant health outcomes. The market is segmented by product type, meal type, and distribution channel, including various formulas and prepared baby foods.
Advertisement

Perrigo to Attend the Jefferies Miami Consumer Conference

https://www.prnewswire.com/news-releases/perrigo-to-attend-the-jefferies-miami-consumer-conference-302936438.html
Perrigo Company plc announced that its Interim President and CEO, Albert Manzone, and CFO, Eduardo Bezerra, are scheduled to participate in investor meetings at the Jefferies Miami Consumer Conference on November 18, 2026. The company, a leading provider of consumer self-care products, will discuss its business and financial condition. The announcement includes important forward-looking statements regarding potential risks and uncertainties.

Perrigo execs to speak at Jefferies Miami Consumer Conference on Nov 18, 2026

https://pluang.com/en/news-feed/perrigo-hadiri-konferensi-konsumen-jefferies-miami
Perrigo Company plc announced that its Interim President and CEO Albert Manzone and CFO Eduardo Bezerra will attend the Jefferies Miami Consumer Conference on November 18, 2026, for investor meetings to discuss the company's self-care products and financial outlook. The company also highlighted the risks associated with forward-looking statements. This news comes as the Consumer Staples sector shows mixed performance, with most US stocks falling on November 11, 2026.

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

https://www.benzinga.com/trading-ideas/dividends/26/11/63027738/wall-streets-most-accurate-analysts-spotlight-on-3-health-care-stocks-delivering-high-dividend-yields-16
During market turbulence, investors often look to dividend-yielding stocks. This article highlights three health care stocks—Perrigo Company PLC (PRGO), Bristol-Myers Squibb Co (BMY), and GSK plc (GSK)—that offer high dividend yields and have recently received analyst ratings from Wall Street's most accurate analysts. It also mentions their recent quarterly results.

Perrigo stock hits 52-week high at $16.81

https://www.investing.com/news/company-news/perrigo-stock-hits-52week-high-at-1681-93CH-5013102
Perrigo Company PLC stock reached a 52-week high of $16.81, trading near its Fair Value with an impressive six-month return of 41.74% and a 7.32% dividend yield. The company recently reported mixed Q3 2026 financial results, exceeding EPS expectations but slightly missing revenue targets due to softer demand. Despite the revenue miss, improved margins and strategic focus were noted positively by investors and analysts.

Perrigo Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:0fa1328df094b:0-perrigo-q3-earnings-call-highlights/
Perrigo (PRGO) reported a decline in third-quarter sales and earnings due to cautious retailer inventory management and weakness in Europe, although the company gained market share. The company updated its 2026 outlook, reflecting the divestiture of its infant formula business and an anticipated slower inventory buildup for the cough and cold season. Interim President and CEO Albert Manzone stated that Perrigo aims to simplify operations and improve consistency.
Advertisement

Learn Why The Bull Case For Perrigo Stock Could Change Following Weaker 2026 Guidance

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/learn-why-the-bull-case-for-perrigo-stock-could-change-follo
Perrigo Company plc reported weaker-than-expected full-year 2026 guidance, with net sales projected to decline 4.6% to 5.7%, alongside a net loss of US$27.5 million for the third quarter. This outlook, coupled with the divestiture of its infant formula unit, shifts the investment narrative towards a sharper focus on core over-the-counter health products. While the company aims for profitability by 2029 with an expected earnings improvement, the dividend coverage remains a risk due to ongoing cash generation pressure.

Perrigo Sets 2026 All-In Adjusted EPS Outlook at $2.25 to $2.45

https://www.tokenpost.com/news/business/49640
Perrigo Company plc has set its 2026 all-in adjusted diluted EPS outlook at $2.25 to $2.45, following the classification of its infant formula unit as discontinued operations. For core operations, the company anticipates adjusted diluted EPS of $2.15 to $2.35, with core reported net sales expected to decline by 2.5% to 3.6% and an adjusted operating margin of 14% to 15%. This strategic move, which includes selling the infant formula unit to MeridianMade for up to $175 million, aims to simplify operations, enhance margin profile, and reduce capital needs.

Quarterly sales fell to $988.6 million as Perrigo (PRGO) swung to a loss.

https://www.stocktitan.net/sec-filings/PRGO/10-q-perrigo-co-plc-quarterly-earnings-report-6fbc2ad893d8.html
Perrigo Company plc (PRGO) reported a third-quarter net loss of $27.5 million, down from a net income of $7.5 million in the prior year, with net sales decreasing to $988.6 million from $1,043.3 million. The nine-month period ending September 26, 2026, also saw a significant net loss of $351.6 million, including $335.9 million in impairment charges. The company completed the divestiture of its Dermacosmetics Business for $362.9 million, resulting in a $129.5 million pretax gain, but continued to face challenges from soft consumption, lower retailer inventory, and increased operating expenses.

Form 8K Perrigo Company plc For: 4 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-perrigo-company-plc-for-4-november-93CH-4929146
This article announces that Perrigo Company plc filed a Form 8K on November 4, 2026. The filing is a standard regulatory disclosure without further details provided in the brief statement. It also notes that the stock symbol PRGO saw a 1.77% increase.

Perrigo Q3 Results: Adjusted EPS $0.60 beats estimate, sales fall 5.18%

https://scanx.trade/stock-market-news/companies/perrigo-q3-results-adjusted-eps-0-60-beats-estimate-sales-fall-5-18/55340095
Perrigo reported adjusted earnings per share of $0.60 for the third quarter, surpassing the analyst consensus estimate of $0.50 by 20%, despite a 25% year-over-year decrease. The company's quarterly sales reached $989 million, narrowly beating estimates by 0.18%, though this represents a 5.18% decline from the previous year. This performance suggests effective cost management or profitability metrics helped offset the revenue contraction, leading to stronger-than-expected earnings.
Advertisement

Form 8K Perrigo Company plc For: 4 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-perrigo-company-plc-for-4-november-93CH-4955903
This article announces that Perrigo Company plc filed a Form 8K on November 4th. The filing is available through Investing.com and is related to stock market news concerning the company. No specific details about the content of the 8K filing are provided in this brief announcement.

Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations

https://www.tradingview.com/news/prnewswire:48ee8e4b283c4:0-perrigo-reports-third-quarter-2026-financial-results-from-continuing-operations/
Perrigo Company plc announced its third-quarter 2026 financial results, reporting a 5.2% decline in All In net sales and a 25.0% decrease in adjusted diluted EPS year-over-year. The company's "Three-S plan" is driving market share gains in U.S. store brand OTC and European brands, and the divestiture of the Infant Formula business is expected to simplify the portfolio and focus on higher-return consumer self-care categories. Perrigo updated its full-year 2026 outlook to reflect the divestiture, measured retailer inventory positioning, and continued softness in Europe.

Profund Advisors LLC Acquires 84,207 Shares of Perrigo Company plc $PRGO

https://www.marketbeat.com/instant-alerts/filing-profund-advisors-llc-acquires-84207-shares-of-perrigo-company-plc-prgo-2026-11-03/
Profund Advisors LLC significantly increased its stake in Perrigo Company plc by 288.3% in the third quarter, acquiring 84,207 shares to bring its total holdings to 113,418 shares, valued at $1.67 million. Despite analyst caution with an average "Reduce" rating and a $18.50 consensus price target, Perrigo reported strong quarterly EPS of $0.50, surpassing estimates, and declared a quarterly dividend of $0.29, offering a 7.3% annualized yield. Institutional investors collectively own 95.91% of the company's stock.

PRGO: Portfolio Focus Matters More, Margin Improvement Now Carries The Bull Case

https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nyse-prgo/perrigo/ol88o6bj-prgo-profit-margins-and-operational-strength-will-support-long-term-upside-potential/updates/16-analysts-have-raised-their-perrigo-price-target-from-dollar1650
Analysts have increased Perrigo's price target from $16.50 to $18.00, reflecting greater confidence in the company's revenue growth, profitability, and future P/E expectations, especially after the divestiture of its Infant Formula business. This strategic move aims to simplify the portfolio and enhance margin profiles by focusing on consumer self-care products. While some analysts see potential for upside, others caution about the reduced margin of safety if profitability assumptions are not met.

Canaccord Genuity Group Forecasts Strong Price Appreciation for Perrigo (NYSE:PRGO) Stock

https://www.marketbeat.com/instant-alerts/analyst-canaccord-genuity-group-forecasts-strong-price-appreciation-for-perrigo-nyse-prgo-stock-2026-11-02/
Canaccord Genuity Group has increased its price target for Perrigo (NYSE:PRGO) stock from $17 to $19, maintaining a "buy" rating and indicating a potential upside of 20.41%. Despite this, analyst sentiment remains mixed, with a consensus "Reduce" rating and an average target price of $18.50 from various analysts. Perrigo recently surpassed quarterly earnings expectations, reporting $0.50 EPS against a $0.39 consensus, though revenue saw a slight decline.
Advertisement

Perrigo Company plc (PRGO) Seasonal returns chart

https://uk.finance.yahoo.com/quote/PRGO/seasonality/
This article from Yahoo Finance focuses on Perrigo Company plc (PRGO), providing a seasonal returns chart. It notes the company's current stock price and highlights a recently announced cash dividend. The page also includes general market information and related tickers.

Perrigo (NYSE:PRGO) Rating Lowered to "Hold" at Wall Street Zen

https://www.marketbeat.com/instant-alerts/analyst-perrigo-nyse-prgo-rating-lowered-to-hold-at-wall-street-zen-2026-10-31/
Wall Street Zen has downgraded Perrigo (NYSE:PRGO) from a "Buy" to a "Hold" rating, aligning with the broader analyst consensus. The company recently reported strong quarterly earnings of $0.50 EPS, exceeding estimates, and provided fiscal 2026 EPS guidance of $2.25-$2.55. Despite institutional ownership of nearly 96%, the stock has seen a slight decline following the downgrade.

Perrigo Company plc (NYSE:PRGO) Shareholders to Receive $0.29 Quarterly Dividend

https://www.marketbeat.com/instant-alerts/dividend-perrigo-company-plc-nyse-prgo-shareholders-to-receive-029-quarterly-dividend-2026-10-30/
Perrigo Company plc (NYSE:PRGO) has declared a quarterly dividend of $0.29 per share, marking its 23rd consecutive year of dividend increases. The dividend, payable on December 15th to shareholders of record on November 27th, represents an annualized payout of $1.16 and a 7.3% yield. Analysts anticipate the dividend will remain covered by projected earnings, with the company's latest EPS of $0.50 surpassing estimates.

Form 8K Perrigo Company plc For: 29 October By Investing.com

https://au.investing.com/news/stock-market-news/form-8k-perrigo-company-plc-for-29-october-93CH-4726345
This article announces that Perrigo Company plc has filed a Form 8K for October 29. The filing, reported by Investing.com, likely contains significant information that the company is required to disclose to the public. The brief notice directs readers to view the full document.

Perrigo: Infant Formula Sale Looks Like a Strategically Sound Move

https://www.morningstar.com/company-reports/1505947-perrigo-infant-formula-sale-looks-like-a-strategically-sound-move?listing=0P000004BF
Perrigo has announced the sale of its infant formula business to MeridianMade for $40 million in cash and up to $135 million in contingent payments. This deal, expected to close in the first half of 2027, saw Perrigo's shares trade sideways. Analyst Keonhee Kim views this as a strategically sound move for the company.
Advertisement

Form 8K Perrigo Company plc For: 29 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-perrigo-company-plc-for-29-october-93CH-2767820
This article from Investing.com announces that Perrigo Company plc filed a Form 8K on October 29. The filing is a standard regulatory disclosure and the article provides the title of the filing along with the company's stock symbol, PRGO.

Perrigo Announces Quarterly Dividend

https://www.tradingview.com/news/prnewswire:a3b0aed4463ca:0-perrigo-announces-quarterly-dividend/
Perrigo Company plc (PRGO) announced its Board of Directors has approved a quarterly dividend of $0.29 per share, totaling $1.16 per share on an annualized basis. The cash dividend is scheduled for payment on December 15, 2026, to shareholders of record as of November 27, 2026. The company, a leading provider of consumer self-care products, also included forward-looking statements regarding potential risks and factors influencing dividend declarations.

Form 8K Perrigo Company plc For: 29 October By Investing.com

https://za.investing.com/news/stock-market-news/form-8k-perrigo-company-plc-for-29-october-93CH-4535830
This article announces that Perrigo Company plc has filed a Form 8K for October 29. The brief report, published by Investing.com, indicates the filing of this regulatory document, which is typically used by public companies to announce significant events that shareholders should know about.

Perrigo Announces Agreement to Divest Infant Formula Business to MeridianMade

https://www.prnewswire.com/news-releases/perrigo-announces-agreement-to-divest-infant-formula-business-to-meridianmade-302923597.html
Perrigo Company plc has entered a definitive agreement to divest its Infant Formula business to MeridianMade for up to $175 million. This move is part of Perrigo's "Three-S plan" to streamline its business and focus on consumer self-care products, enhancing its margin profile and reducing future capital expenditures. MeridianMade, an American contract manufacturing platform specializing in infant nutrition, will acquire the business, with the transaction expected to close in the first half of 2027.

Form 8K Perrigo Company plc For: 29 October By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-perrigo-company-plc-for-29-october-93CH-4942092
This article reports on the filing of a Form 8K by Perrigo Company plc on October 29, 2026. Form 8K filings are used by companies to announce major events that shareholders should know about. The article itself does not provide further details on the content of the Form 8K.
Advertisement

Perrigo Company plc (PRGO) To Sell Infant Formula Unit For Up To $175M

https://www.tradingview.com/news/tradingview:289f2c24565b7:0-perrigo-company-plc-prgo-to-sell-infant-formula-unit-for-up-to-175m/
Perrigo Company plc (PRGO) has entered an agreement to sell its Infant Formula business to MeridianMade for up to $175 million, including $40 million at closing and up to $135 million in milestones. The sale is expected to close in the first half of 2027 and is part of Perrigo's strategy to focus on its self-care portfolio, exiting a low-margin and capital-intensive unit. Perrigo anticipates a non-cash impairment charge of $275-$375 million in Q4 2026 due to the divestment.

Form 8K Perrigo Company plc For: 29 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-perrigo-company-plc-for-29-october-93CH-4914154
This article announces that Perrigo Company plc (PRGO) filed a Form 8K on October 29, 2026. The Form 8K is a crucial document that companies file with the SEC to announce major events that shareholders should know about. No specific details about the content of the Form 8K are provided in this brief announcement.

Perrigo to sell infant formula business in deal worth up to $175M

https://www.crainsgrandrapids.com/consumer-products/cgr-perrigo-sells-infant-formula-business-meridianmade-20261029/
Perrigo Co. plc has announced its intent to sell its infant formula business to MeridianMade in a deal potentially worth up to $175 million. The North American headquarters of Perrigo is located in Grand Rapids. This transaction will allow Perrigo to streamline its business focus.

Perrigo Company PLC Shs Unsponsored Brazilian Depositary Receipt Repr 1 Sh

https://www.tradingview.com/symbols/BMFBOVESPA-P1RG34/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/
This article focuses on the enterprise value to EBITDA forward for Perrigo Company PLC Shs Unsponsored Brazilian Depositary Receipt Repr 1 Sh (P1RG34) traded on B3. It provides a snapshot of its financial metrics. The piece indicates that the market is closed with no trades recorded for this specific security.

Perrigo to Release Third Quarter 2026 Financial Results on November 4, 2026

https://www.streetinsider.com/PRNewswire/Perrigo+to+Release+Third+Quarter+2026+Financial+Results+on+November+4%2C+2026/27213632.html
Perrigo Company plc announced it will release its third-quarter 2026 financial results on Wednesday, November 4, 2026. The company will host a conference call at 8:30 a.m. ET with Interim President and CEO Albert Manzone and CFO Eduardo Bezerra to discuss the results. A webcast and phone replay will be available for interested parties.
Advertisement

116,170 Shares in Perrigo Company plc $PRGO Acquired by TD Waterhouse Canada Inc.

https://www.marketbeat.com/instant-alerts/filing-116170-shares-in-perrigo-company-plc-prgo-acquired-by-td-waterhouse-canada-inc-2026-10-22/
TD Waterhouse Canada Inc. recently acquired 116,170 shares of Perrigo Company plc (NYSE:PRGO) in the third quarter, valued at approximately $1.62 million, representing 0.08% of the company. Institutional investors collectively own 95.91% of Perrigo's stock, which currently holds a consensus "Hold" rating from analysts with an average price target of $19.33. The company also announced a quarterly dividend of $0.29, offering a 7.3% annualized yield.

Perrigo Company plc $PRGO Stock: Cooke & Bieler LP Reduces Stake

https://www.marketbeat.com/instant-alerts/filing-perrigo-company-plc-prgo-stock-cooke-bieler-lp-reduces-stake-2026-10-22/
Cooke & Bieler LP reduced its stake in Perrigo Company plc (NYSE:PRGO) by 12.8% during the third quarter, selling 151,628 shares. Despite this, other hedge funds increased their positions, with institutional investors now owning 95.91% of the stock. Perrigo reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $0.29 per share.

Perrigo Co. PLC stock underperforms Wednesday when compared to competitors

https://www.marketwatch.com/data-news/perrigo-co-plc-stock-underperforms-wednesday-when-compared-to-competitors-912c4da7-8410a9ee3640?mod=goog_fin_scmw
Shares of Perrigo Co. PLC (PRGO) fell 1.61% on Wednesday to $15.91, despite a generally positive trading session for the broader stock market, with both the S&P 500 and Dow Jones Industrial Average seeing gains. The company's stock closed 27.75% below its 52-week high.

Perrigo to Release Third Quarter 2026 Financial Results on November 4, 2026

https://www.morningstar.com/news/pr-newswire/20261021de77399/perrigo-to-release-third-quarter-2026-financial-results-on-november-4-2026
Perrigo Company plc (NYSE: PRGO) announced it will release its third quarter 2026 financial results on Wednesday, November 4, 2026. The company will host a conference call at 8:30 a.m. ET, available via webcast and phone, featuring Interim President and CEO Albert Manzone and CFO Eduardo Bezerra. A replay of the call will be accessible from November 4 to November 11, 2026.

Perrigo to Release Third Quarter 2026 Financial Results on November 4, 2026

https://finance.yahoo.com/markets/stocks/articles/perrigo-release-third-quarter-2026-123000263.html
Perrigo Company plc announced it will release its third-quarter 2026 financial results on Wednesday, November 4, 2026. The company will host a conference call at 8:30 a.m. ET with Interim President and CEO Albert Manzone and CFO Eduardo Bezerra to discuss the results. A webcast and phone replay will be available for those unable to attend the live call.
Advertisement

Perrigo Co. PLC stock underperforms Monday when compared to competitors

https://www.marketwatch.com/data-news/perrigo-co-plc-stock-underperforms-monday-when-compared-to-competitors-b4da9656-09f55bf928cc?mod=goog_fin_scmw
Perrigo Co. PLC (PRGO) shares fell 3.25% to $16.09 on Monday, underperforming the broader market. This decline occurred despite a mixed trading session where the S&P 500 Index rose, and the Dow Jones Industrial Average slightly fell. The stock's drop ended a three-day winning streak.

Perrigo Company plc (NYSE:PRGO) Stock Rated "Hold" by Sell-Side Analysts

https://www.marketbeat.com/instant-alerts/consensus-perrigo-company-plc-nyse-prgo-stock-rated-hold-by-sell-side-analysts-2026-10-13/
Perrigo Company plc (NYSE:PRGO) has received an average "Hold" rating from sell-side analysts, with a consensus 12-month price target of $19.33 against a recent price of $15.39. Institutional investors hold a significant 95.91% of the stock, and several major firms increased their positions recently. The company beat quarterly EPS estimates but saw a 3.1% decline in revenue year-over-year and pays a quarterly dividend of $0.29 per share, yielding 7.5%.

Perrigo may have attracted takeover interest - Betaville

https://seekingalpha.com/news/4651854-perrigo-may-have-attracted-takeover-interest-betaville
Perrigo (PRGO) may be attracting takeover interest from an undisclosed buyer. Speculation suggests that CVC Capital could be considering acquiring Perrigo to merge it with its Cooper Consumer Health company, according to traders citing a Betaville "uncooked" alert.

Perrigo Company plc $PRGO Shares Bought by O Keefe Stevens Advisory Inc.

https://www.marketbeat.com/instant-alerts/filing-perrigo-company-plc-prgo-shares-bought-by-o-keefe-stevens-advisory-inc-2026-10-09/
O Keefe Stevens Advisory Inc. significantly increased its stake in Perrigo Company plc ($PRGO) by 9.6% in the third quarter, acquiring over 80,000 additional shares, bringing their total holdings to 915,885 shares valued at approximately $13.5 million. Other institutional investors also adjusted their positions, with overall institutional ownership remaining high at 95.91%. Analysts currently hold a consensus "Hold" rating on Perrigo with a price target of $19.33, and the company recently reported strong quarterly earnings and maintains a substantial dividend yield.

Perrigo Co. PLC stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/perrigo-co-plc-stock-outperforms-competitors-on-strong-trading-day-4a798a10-df55099db9c4?mod=goog_fin_scmw
Perrigo Co. PLC (PRGO) saw its stock rally by 3.93% to $14.55 on a day when the broader market, including the S&P 500 and Dow Jones Industrial Average, experienced declines. Despite this positive performance, the company's stock closed 34.49% below its 52-week high.
Advertisement

Perrigo Co. PLC stock underperforms Tuesday when compared to competitors

https://www.marketwatch.com/data-news/perrigo-co-plc-stock-underperforms-tuesday-when-compared-to-competitors-3d7eba86-de4c59779534?mod=goog_fin_scmw
Perrigo Co. PLC (PRGO) stock experienced a 3.05% decline on Tuesday, closing at $14.00, despite a generally positive trading day for the broader market. This underperformance broke a two-day winning streak for the company's shares. The S&P 500 Index and Dow Jones Industrial Average both saw increases during the same trading session.

PRGO4068018 Bond Profile: Coupon and Redemption

https://www.tradingview.com/symbols/FINRA-PRGO4068018/profile/
This article provides a detailed profile of the PRGO4068018 bond issued by Perrigo Company plc. It outlines key facts such as the issuer, issue and maturity dates, face value, coupon rate of 5.30%, and minimum denomination. The profile also covers classification details, credit risk assessment information, and redemption specifics for the bond.

Perrigo stock soars 62% after InvestingPro Fair Value call By Investing.com

https://www.investing.com/news/investment-ideas/perrigo-stock-soars-62-after-investingpro-fair-value-call-93CH-4931730
Perrigo Company plc (NYSE:PRGO) stock surged 61.8% to $15.42 by September 27, 2026, after InvestingPro's Fair Value models identified it as significantly undervalued in March 2026, when it was trading at $9.53. The rally validated InvestingPro's multi-factor valuation approach, which combines various models to identify mispriced opportunities and provide comprehensive intrinsic value estimates. This success story highlights the effectiveness of Fair Value analysis in helping investors make informed decisions.

PERRIGO COMPANY PLC Share Price Live Today – NYSE:PRGO Stock Price, Chart, News, History

https://upstox.com/us-stocks/prgo-share-price/
This article provides a comprehensive overview of PERRIGO COMPANY PLC's (NYSE: PRGO) stock performance as of September 30, 2026. It details the current share price, intraday and 52-week ranges, trading volume, and key financial fundamentals including market capitalization, P/E ratio, dividend yield, and recent quarterly and annual profit and loss statements. The article also includes historical returns and an "About Us" section for the company.

PRGO4068021 Bond Profile: Coupon and Redemption

https://www.tradingview.com/symbols/FINRA-PRGO4068021/profile/
This article provides a detailed profile of the Perrigo Company plc bond, PRGO4068021, featuring its 5.3% coupon rate and a maturity date of November 15, 2043. It outlines key facts such as issuer information, issue and maturity dates, face value, and minimum denomination. The bond profile also touches on the company's nature as a self-care product provider and mentions aspects like credit risk assessment and interest payment details.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement